[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"TBF Genie Tissulaire\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":156},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,66,91,111,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100626433","phase-2-use-of-a-treated-devitalized-and-sterile-umbilical-cord-amniotic-membrane-in-the-treatment-of-trapeziometacarpal-osteoarthritis-100626433",false,"NCT07435571","Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of Trapeziometacarpal Osteoarthritis","Evaluation of the Treatment of Trapeziometacarpal Osteoarthritis (TMC OA) With a Treated, Devitalized and Sterile Amniotic Membrane of Umbilical Cord Placed in Joint Interposition","Inclusion Criteria:\n\n* Patient presenting with symptomatic osteoarthritis of the trapeziometacarpal joint, with wrist pain ≥ 40\u002F100 according to the PRWE pain subscale (scaled to 100).\n* Patient who has received medical treatment for functional symptoms for more than 3 months without improvement, and for whom surgical intervention is indicated.\n* Patient with radiographic stage I-II trapeziometacarpal joint osteoarthritis according to the Eaton-Glickel classification.\n* Patient able to understand, date, and sign the informed consent form.\n* Patient affiliated with a social security system or beneficiary of such a system.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman ; woman without effective contraception.\n* Patient with scaphotrapeziotrapezoid (STT) joint osteoarthritis requiring prosthetic surgical treatment.\n* Patient with thumb osteoarthritis secondary to a systemic inflammatory disease (e.g., rheumatoid arthritis).\n* Patient with osteoarthritis experiencing an acute inflammatory flare, characterized by a warm, painful, and swollen joint at the time of enrollment.\n* Patient with amputated hand(s).\n* Patient presenting signs of neuropathy with functional impairment such as hyperesthesia. Neuropathy may be peripheral (nerve injury) or systemic (caused by diabetes or excessive alcohol consumption).\n* Patient lacking capacity to participate in rehabilitation or to comply with study follow-up.\n* Patient with a contraindication to anesthesia (poorly controlled epilepsy, neuropathy, etc.).\n* Person deprived of liberty by a judicial or administrative decision.\n* Adult subject under legal protection or unable to provide informed consent.","ALL","18 Years","75 Years",{"count":20,"type":21},22,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The objective of this clinical trial is to evaluate whether a human umbilical cord amniotic membrane allograft can serve as an interposition implant in the surgical treatment of trapeziometacarpal osteoarthritis.\n\nThe main question this study aims to address is :\n\n\\- Can interposition of a human umbilical cord amniotic membrane within the trapeziometacarpal joint reduces postoperative pain and improves thumb mobility, grip and pinch strength, and overall wrist function.\n\nParticipant will:\n\n* Undergo surgical treatment of the trapeziometacarpal osteoarthritis with the interposition in articular joint of an amniotic membrane of umbilical cord allograft on Day 0\n* Visit the center for a series of tests 1 month, 3 months, 6 months and 12 months after the surgical intervention.",[27],"Trapeziometacarpal Osteoarthritis",[29],"TMC OA","NOT_YET_RECRUITING","2026-02-20",{"date":33,"type":34},"2026-02-27","ACTUAL",{"date":36,"type":21},"2026-03",{"date":38,"type":21},"2028-03",{"name":40,"class":41},"TBF Genie Tissulaire","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100568266","phase-3-treated-umbilical-vein-allograft-uvt-versus-autologous-fascial-pubovaginal-sling-in-the-treatment-of-female-stress-urinary-incontinence-100568266","NCT06678984","Treated Umbilical Vein Allograft (UVT) Versus Autologous Fascial Pubovaginal Sling in the Treatment of Female Stress Urinary Incontinence","Inclusion Criteria:\n\n* Women aged 18 to 85 years.\n* Patients with stress urinary incontinence or mixed urinary incontinence with a predominant stress component.\n* Patients with stress urinary incontinence due to cervico-urethral hypermobility or urethral hypermobility.\n* Patients with urethral hypermobility confirmed by Ulmsten suburethral support maneuver.\n* Urinary incontinence demonstrated by one-hour pad test.\n* Patients with significant and persistent discomfort despite perineal rehabilitation.\n* Patients able to understand the information concerning the study and having voluntarily dated and signed the informed consent form.\n* Patients able and willing to comply with the requirements and instructions of the study.\n* Patients who are members or the beneficiary of a national health insurance plan.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women or those not using effective contraception.\n* Patients with a body mass index (BMI) ≥ 35 kg\u002Fm2.\n* Patients with moderate stress urinary incontinence treated with physiotherapy and pelvic support exercises.\n* Patients with voiding disorders or at risk of performing self-catheterization.\n* Patients who have already undergone surgical treatment for urinary incontinence.\n* Patients unable to perform the pad test or unwilling to perform it at each follow-up visit.\n* Patients considered by the principal investigator to be poor candidates for surgical procedures and\u002For anesthesia due to their physical or mental state.\n* Patients with current urinary tract infection, severe anemia, uncontrolled diabetes or other conditions contraindicating surgery.\n* Patients with neurogenic bladder.\n* Patients with a history of conditions, illnesses or surgical procedures that may confound the results of the urinary incontinence assessment, including but not limited to: pelvic organ prolapse (e.g., cystocele, rectocele), neurological disorders (e.g., multiple sclerosis, Parkinson's disease), recurrent urinary tract infections, recurrent bladder stones, interstitial cystitis, history of pelvic irradiation (external beam therapy or brachytherapy), current diagnosis of genitourinary malignancy.\n* Patients deprived of liberty by a judicial or administrative decision.\n* Patients incapable of discernment for rehabilitation, unable to follow up or give consent.","FEMALE","85 Years",{"count":51,"type":21},96,[53],"PHASE3","The goal of this clinical trial is to evaluate whether a treated umbilical vein allograft is effective in treating stress urinary incontinence in females. The researchers will compare the treated umbilical vein allograft with a sling made of autologous tissue. The main question the clinical trial aims to answer is:\n\n\\- Is the treated umbilical vein allograft as effective as the sling made of autologous tissue for treating female stress urinary incontinence?\n\nParticipants will:\n\n* Undergo surgical treatment with either the umbilical vein allograft or the sling made of autologous tissue on Day 0.\n* Visit the hospital for a series of tests at 3 weeks, 3 months, 6 months, and 12 months after the surgical intervention.\n* Record their bladder activity between each hospital visit.",[56],"Stress Urinary Incontinence in Women","2025-09-24",{"date":59,"type":34},"2025-09-30",{"date":61,"type":21},"2025-10",{"date":63,"type":21},"2028-05-01",{"name":40,"class":41},8,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100518724","phase-2-use-of-a-treated-devitalized-and-sterile-umbilical-cord-amniotic-membrane-in-the-treatment-of-pip-joint-osteoarthritis-100518724","NCT06034262","Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis","Evaluation of the Treatment of Symptomatic Proximal InterPhalangeal (PIP) Joint Osteoarthritis With a Treated, Devitalized and Sterile Amniotic Membrane of Umbilical Cord Placed in Joint Interposition","Inclusion Criteria:\n\n* Male or female; age between 18 and 75 years.\n* Patient with symptomatic PIPJ OA.\n* Patient treated medically for functional signs for more than 3 months, without improvement, justifying a surgical intervention.\n* Patient with a QuickDash score \\> 33 points (converted to 50%).\n* Patient with pain, at rest, in the PIPJ ≥ 4\u002F10 on a VAS.\n* Patient who received the study information and provided consent.\n* Member or beneficiary of a national health insurance plan.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman; woman without effective contraception.\n* Patient with signs of neuropathy with functional disorders such as hyperesthesia.\n* Patient with uncontrolled epilepsy or neuropathy that contraindicates locoregional anesthesia.\n* Person confined by a judicial or administrative decision.\n* Adult subjected to legal protection measures or unable to provide his\u002Fher consent.",{"count":74,"type":21},14,[24],"The aim of this open, prospective, multicenter trial is to evaluate the use of a sterile, devitalized, processed umbilical cord amniotic membrane implant placed in joint interposition in the treatment of PIP joint osteoarthritis.",[78],"Osteoarthritis Hand",[80,81],"Proximal InterPhalangeal Joint (PIPJ)","OsteoArthritis (OA)","RECRUITING",{"date":84,"type":34},"2025-09-26",{"date":86,"type":34},"2024-10-07",{"date":88,"type":21},"2026-01",{"name":40,"class":41},3,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100519037","phase-2-use-of-a-treated-devitalized-and-sterile-umbilical-cord-amniotic-membrane-in-the-treatment-of-stt-osteoarthritis-100519037","NCT06038331","Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis","Evaluation of the Treatment of Symptomatic Scaphotrapeziotrapezoidal (STT) Osteoarthritis With a Treated, Devitalized and Sterile Amniotic Membrane of Umbilical Cord Placed in Joint Interposition","Inclusion Criteria:\n\n* Male or female; age between 18 and 75 years.\n* Patient with symptomatic STT OA.\n* Patient treated medically for functional signs for more than 3 months, without improvement, justifying a surgical intervention.\n* Patient with a QuickDash score \\> 33 points (converted to 50%).\n* Patient with wrist pain in front of the STT joint at rest = or \\> 4\u002F10 on VAS.\n* Patient who received the study information and provided consent.\n* Member or beneficiary of a national health insurance plan.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman; woman without effective contraception.\n* Patient with functional rhizarthrosis that has not been stabilized or treated medically or surgically.\n* Patient with signs of neuropathy with functional disorders such as hyperesthesia.\n* Patient with uncontrolled epilepsy or neuropathy that contraindicates locoregional anesthesia.\n* Person confined by a judicial or administrative decision.\n* Adult subjected to legal protection measures or unable to provide his\u002Fher consent.",{"count":74,"type":21},[24],"The aim of this open, prospective, multicenter trial is to evaluate the use of a sterile, devitalized, processed umbilical cord amniotic membrane implant placed in joint interposition in the treatment of STT osteoarthritis.",[78],[103],"ScaphoTrapezioTrapezoid OsteoArthritis (STT OA)",{"date":59,"type":34},{"date":106,"type":34},"2024-05-28",{"date":108,"type":21},"2026-12",{"name":40,"class":41},4,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100550699","phase-3-use-of-a-freeze-dried-amniotic-membrane-post-crosslinking-in-subjects-with-progressive-keratoconus-100550699","NCT06450470","Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus","Multicenter, Randomized Study Evaluating the Use of a Non-sutured Sterile Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus","Inclusion Criteria:\n\n* Man or woman between 18 and 65 years old.\n* Indication for accelerated conventional crosslinking.\n* Patient with progressive keratoconus (increase in Kmax of ≥ 0.5 diopters in 3 to 6 months or ≥ 1 diopter in 3 to 12 months with loss of 10 microns on minimum pachymetry in 3 to 12 month).\n* Patient suffering from keratoconus with a compatible topographic form (Kmax ≥ 47.0 diopters (D) and difference inferior-superior of 1.5 D).\n* Patient with a minimum corneal thickness greater than 400 microns.\n* Informed and consenting patient.\n* Patient physically and mentally capable of completing the post-operative pain assessment self-questionnaire.\n* Patient having signed the informed consent of the French Ophthalmology Society for crosslinking.\n* Patient affiliated to a social security system or beneficiary of such a system.\n\nExclusion Criteria:\n\n* Woman without effective means of contraception, pregnant or breastfeeding.\n* Patient who has already benefited from a crosslinking procedure on one of the eyes.\n* Patient with a history of refractive surgery on one of the eyes.\n* Patient with an intracorneal ring segment on one of the eyes.\n* Patient suffering from a serious systemic pathology (autoimmune and\u002For immunodepressive)\n* Patient with a psychiatric pathology.\n* Patient on long-term analgesics and\u002For corticosteroids.\n* Indication of crosslinking outside the classic protocol.\n* Patient with central corneal opacity.\n* Patient suffering from a severe dry eye syndrome or a neurotrophic keratitis.\n* Patient with a history of ocular herpes.\n* Patient with a history of ocular varicella-zoster virus infection.\n* Patient with glaucoma.\n* Patient treated with topical cyclosporine in the last 6 months.\n* Patient deprived of liberty by a judicial or administrative decision.\n* Patient subject to a legal protection measure or unable to express their consent.","65 Years",{"count":120,"type":21},116,[53],"Crosslinking is a therapeutic technique used to increase the rigidity of the cornea in order to slow or stop progression of keratoconus. The main complication of the treatment of keratoconus by crosslinking is postoperative pain due to the removal of the corneal epithelium. Currently, the management of pain is done through the administration of artificial tears and paracetamol. The amniotic membrane is a biological tissue used in ophthalmology to treat injuries of the surface of the eye. It has healing and analgesic properties.\n\nThe objective of this multicenter randomized study is to evaluate the benefit of placing an amniotic membrane on the eye post-crosslinking to reduce pain and promote corneal healing.",[124],"Progressive Keratoconus","2025-04-08",{"date":127,"type":34},"2025-04-11",{"date":129,"type":34},"2024-11-25",{"date":131,"type":21},"2025-11",{"name":40,"class":41},9,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},"100571709","phase-2-surgical-release-of-hand-tendons-with-wrapping-of-the-released-tendon-using-an-amniotic-membrane-100571709","NCT06723782","Surgical Release of Hand Tendons with Wrapping of the Released Tendon Using an Amniotic Membrane","Inclusion Criteria:\n\n* Man or woman aged 18 to 65 years old\n* Adhesion of a flexor and\u002For extensor tendon of the hand.\n* Adhesion localized to a single finger.\n* Adhesion that has been present for at least 3 months following primary repair, despite high-quality rehabilitation. Primary repair is defined as the repair of a tendon injury, fracture, crush injury of the finger, infection, etc., leading to the adhesion of the tendon to surrounding tissue.\n* Patient with a total passive range of motion of the proximal and distal interphalangeal joints of at least 150°.\n* Informed and consenting patient.\n* Patient enrolled in a social security plan or a beneficiary of such a plan.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman, or without an effective method of contraception.\n* Patient requiring tenolysis after tendon grafting for the reconstruction of a deep common flexor or after reimplantation.\n* Patient with amputated hand(s).\n* Patient with an untreated fracture or non-union in the affected hand.\n* Patient requiring multiple surgical interventions that may be potential confounding factors, particularly those involving additional incisions.\n* Patient unable to understand rehabilitation or follow the study protocol.\n* Patient with a contraindication to anesthesia.\n* Person deprived of liberty by judicial or administrative decision.\n* Adult subject to legal protection measures or incapable of expressing consent.",{"count":141,"type":21},16,[24],"The goal of this clinical trial is to evaluate whether an amniotic membrane can function as an effective anti-adhesive barrier following surgical release of tendon adhesions. The main question the clinical trial aims to answer is:\n\n\\- Can wrapping an amniotic membrane around a surgically released tendon help reduce recurrence of adhesions and promote recovery of hand functionality?\n\nParticipants will:\n\n* Undergo surgical treatment (surgical release of the tendon adhesions and wrapping of the amniotic membrane around the release tendon) on Day 0.\n* Visit the center for a series of tests 15 days, 6 weeks, 3 months, 6 months after the surgical intervention.",[145,146],"Tendon Adhesion","Tenolysis","2024-12-04",{"date":149,"type":34},"2024-12-09",{"date":151,"type":34},"2024-02-15",{"date":153,"type":21},"2026-08",{"name":40,"class":41},1,""]